Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOF/VEL plus prophylactic TAF for treatment-naive HCV/HBV coinfected adults in China
ChiCTR2000033390Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jun 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sofosbuvir, velpatasvir and tenofovir alafenamide in hepatitis C virus infection and hepatitis B (HBV) (2 arms), sponsored by Peking University First Hospital. Primary endpoints: HCV RNA quantification and Safety. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
sofosbuvirvelpatasvirtenofovir alafenamide
03
Conditions
hepatitis C virus infectionhepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR2000033390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033390.